The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,370.00
Bid: 12,370.00
Ask: 12,374.00
Change: 38.00 (0.31%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Opening snapshot: buying retailers, eyes on the Fed

Wed, 16th Sep 2020 08:44

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Danilo Masoni
(danilo.masoni@thomsonreuters.com) and Stefano Rebaudo (stefano.rebaudo@thomsonreuters.com) in
Milan.

OPENING SNAPSHOT: BUYING RETAILERS, EYES ON THE FED (0743 GMT)

European stocks are slightly higher, supported by the retail sector after stronger than
expected results from Zara owner Inditex.

Investors are reluctant to take big positions ahead of today's Federal Reserve policy
meeting. Their focus is on the central bank's economic view with some expectations it might take
further steps on the accommodative side.

Travel and leisure stocks are still under pressure after Lufthansa said it could
cut its fleet by 130 planes, 30 planes more than recently panned.

Europe's STOXX 600 index is up 0.2% led by Retailers, up 1.4%, while Travel and
Leisure stocks are the worst performers, down 0.4%

Inditex is up 5.5% after the company returned to quarterly profit though reported
sales down 31% on the year-ago period. Sweden’s Handelsbanken is up 3.3% as the
company will reduce its workforce and number of branches.

A whooping 30% rise for The Hut Group in its first day of trading on the London
Stock Exchange to seal the first major British initial public offering since the start of the
COVID-19 crisis.

(Stefano Rebaudo)

*****

ON THE RADAR: ASTRAZENECA, THE HUT GROUP, HANDELSBANKEN (0644 GMT)

European stocks are set to open slightly lower as investors wait for Federal Reserve policy
statement and economic view later today.

Vaccine developments are still on the frontline after the U.S. Food and Drug Administration
confirmed AstraZeneca's U.S. COVID-19 vaccine trial is on hold, as it conducts its
investigation after an illness in a participant in Britain.

Meanwhile in India, the local drugs regulator has given approval to Serum Institute of India
to resume clinical trials of the potential vaccine developed by AstraZeneca and Oxford
University, according to a Times of India report.

In London, e-commerce firm The Hut Group is preparing for its first day of trading
after batting away corporate governance concerns to seal the first major British initial public
offering since the start of the COVID-19 crisis.

Elsewhere, Handelsbanken will reduce its number of branches to around 200 from 380
by the end of 2021 and reduce its workforce, affecting around 1,000 employees in Sweden over the
next two years, as part of a review of the group's business operations.

Eyes also on Lufthansa which could cut its fleet by 130 planes in response to the
coronavirus crisis, 30 planes more than recently panned.

In results, fashion retailer Inditex, owner of Zara, returned to quarterly profit
in the three months from May to July but reported sales down 31% on the year-ago period.

There could be a positive readacross for Deutsche Post and Royal Mail
from stronger than expected results at U.S. delivery firm FedEx.

Finally Atlantia is ready to approve the listing of its motorway assets as early as
next week, challenging the solution favoured by the Rome government to solve a long-running
dispute with the infrastructure group.

(Stefano Rebaudo)

*****

MORNING CALL: WAITING FOR THE FED (0528 GMT)

European stock futures are hovering around yesterday levels with no clear direction as
investors await a Federal Reserve policy statement later today.

Yesterday’s upbeat U.S. and China macro data increased risk sentiment, but concerns about
the economy remain on fears of a second wave of virus-induced restrictions as well as a
political impasse over a new relief package in the U.S.

The Fed policy meeting which ends today is the first one since chairman Jerome Powell
announced a new stance on inflation and some analysts hope the U.S. central bank might take a
step forward on the accommodative side.

(Stefano Rebaudo)

*****

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.